Clinical Trials Logo

Filter by:
NCT ID: NCT00548405 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

CARE-MS II
Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.

NCT ID: NCT00548262 Completed - Candidemia Clinical Trials

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.

NCT ID: NCT00547807 Unknown status - Pain Clinical Trials

Non-Nutritive Sucking and Swaddling for Pain Relief in Term Neonates: Randomised Controlled Trial

Start date: January 2007
Phase: N/A
Study type: Interventional

Non pharmacological approaches are important in pain control in neonates, specially in term healthy neonates. Non-nutritive sucking and swaddling are considered effective strategies for pain control in these population, but the effect in their association are not clear until now. The hypothesis of the study is that association between non-nutritive sucking and swaddling reduces pain scores resulting from venepuncture compared to non-nutritive sucking alone.

NCT ID: NCT00547287 Completed - Impotence Clinical Trials

Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations

Start date: November 2002
Phase: Phase 3
Study type: Interventional

Study to determine if men from around the world prefer sildenafil to tadalafil.

NCT ID: NCT00546637 Completed - Clinical trials for Overactive Bladder Syndrome

Fesoterodine "add-on" Male Overactive Bladder Study

Start date: November 2007
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

NCT ID: NCT00545805 Completed - Obesity Clinical Trials

Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity

Start date: October 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The intraabdominal fat is associated with insulin resistance, a condition that is in the basis of diabetes, metabolic syndrome and some cardiovascular diseases. It is not clear whether it is the origin of it or a surrogate marker only. We intend to compare the effects of bariatric surgery with versus without omentectomy in morbidly obese people intended to go through bariatric surgery, accessing insulin sensitivity by metabolic tests. If the visceral fat is causative of insulin resistance, its surgical removal (omentectomy) might lead to improvement of insulin action, as seen in animal studies and in one study with morbidly obese human volunteers.

NCT ID: NCT00545688 Completed - Breast Cancer Clinical Trials

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

Start date: June 2006
Phase: Phase 2
Study type: Interventional

This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Before surgery, patients will be randomized to one of 4 treatment arms, to receive 4 cycles of a)Herceptin + docetaxel b)Herceptin + docetaxel + pertuzumab c)Herceptin + pertuzumab or 4)pertuzumab + docetaxel. Pertuzumab will be administered at a loading dose of 840mg iv, then 420mg iv 3-weekly, Herceptin at a loading dose of 8mg/kg iv then 6mg/kg 3-weekly, and docetaxel at a dose of 75mg/m2 escalating to 100mg/m2 3-weekly. During the entire pre- and post-surgery period all patients will receive adequate chemotherapy as per standard of care, as well as any surgery and/or radiotherapy as required. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

NCT ID: NCT00545532 Completed - Influenza, Human Clinical Trials

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Start date: February 4, 2008
Phase: Phase 3
Study type: Interventional

This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the development of resistant influenza virus. Eligible immunocompromised participants with laboratory-confirmed influenza will be randomized to receive either conventional dose (30 milligrams [mg] to 75 mg twice daily orally [po], depending on age and weight) or double dose (60 mg-150 mg twice daily po depending on age and weight) olseltamivir for 10 days. Nasal and throat swabs will be taken, and safety evaluations made, at intervals during the study. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.

NCT ID: NCT00545428 Completed - Clinical trials for Nose Deformities, Acquired

Mastoid Bone Autograft for Dorsal Nasal Augmentation

Start date: April 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of mastoid bone autograft for dorsal nasal augmentation in rhinoplasty.

NCT ID: NCT00545103 Completed - Diverticulitis Clinical Trials

Prevention of Recurrence of Diverticulitis

PREVENT2
Start date: December 6, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis.